The global atopic dermatitis drugs market size is expected to
reach USD 6.41 billion by 2022, according to a new report by Grand View
Research, Inc., exhibiting a CAGR of 6.6% during the forecast period. Various
factors such as emergence of novel therapeutics and growing uptake of targeted
therapies are stimulating the growth of the market.
Eucrisa (Pfizer; crisaborole ointment)
was approved by the U.S. FDA for treatment of atopic dermatitis (AD), in 2016.
The drug is indicated for mild-to-moderate AD in patients who are two years or
older, meeting a key therapeutics need of the market. Dupixent
(Sanofi/Regeneron) was the first biologic to be launched in 2017 for management
of AD. The drug is under clinical investigation for use in pediatric
population.
Several promising candidates,
especially biologics and small molecules, in pipeline are expected to alter the
AD therapeutic landscape post launch. Nemolizumab is anticipated to be the
first biologic (anti-IL-13) indicated for itching associated with atopic
dermatitis. Tralokinumab, an IL-13 inhibitor, is under evaluation for safety
and efficacy of treatment of moderate-to-severe AD.
Upcoming patent expiration of key
products, such as LEO Pharma’s Protopic, Mylan/Valeant’s Elidel, and Bayer’s
Desonate will result in generic penetration in therapeutic space. However,
novel therapeutics, such as Eucrisa and Dupixent, are likely to gain traction
over the forecast period and attain blockbuster status.
Underdeveloped and unserved categories
such as rarer subtypes and pediatric population offer strong commercial
opportunities. Drug companies are currently investigating multiple treatment
options in niche indications such as severe refractory atopic dermatitis.
Improving availability of new treatment modalities and targeted approaches
offer a promising future for the global atopic dermatitis drugs market.
Browse full research report on Atopic Dermatitis Drugs Market: https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market
Further key findings from the report suggest:
- Corticosteroids dominated the drug class in 2016, owing to
their indication as first-line therapeutics for atopic dermatitis
- Recent launch of biologics and small molecules such as
Dupixent and Eucrisais likely to change the current therapeutic scenario
due to their target-oriented mechanism of action
- Calcineurin inhibitors are likely to witness stifled growth
because of adverse effects, non-specificity, and development of resistance
to chemical agents
- The U.S. was the leading regional market in 2016. It is posed
to maintain its position through 2022, owing to burgeoning disease burden,
increasing treatment rate, and high drug cost
- The topical segment led the atopic dermatitis drugs market in
2016, based on route of administration. Although the segment is expected
to continue leading the market through 2022, Dupixent’s launch in 2017
marked the arrival of injectable. The new RoA is anticipated to hold
approximately 30.0% market share by 2022
- Bayer, LEO Pharma, Mylan, Pfizer, and Sanofi are some of key
players operating in the market
- Pfizer and Sanofi are anticipated to be leaders in AD
therapeutic space by 2022 due to growing adoption of targeted therapies,
such as Eucrisa and Dupixent
- Rarer subtypes, such as severe refractory atopic dermatitis,
have few treatment options available and lack a significant pipeline. This
field presents a strong commercial opportunity to drug developers.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-drugs-market/request/rs1
Grand View Research has segmented the global atopic dermatitis
drugs market based on drug class, route of administration, and region:
Atopic Dermatitis Drugs Class Outlook (Revenue, USD Million,
2016 - 2022)
- Corticosteroids
- Calcineurin
Inhibitors
- PDE4
Inhibitors
- Biologics
- Others
Atopic Dermatitis Drugs Route of Administration Outlook
(Revenue, USD Million, 2016 - 2022)
- Topical
- Injectable
- Oral
Atopic Dermatitis Drugs Regional Outlook (Revenue, USD
Million, 2016 - 2022)
- U.S.
- U.K.
- Germany
- Spain
- France
- Italy
- Japan
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
No comments:
Post a Comment